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Background: The state of tolerance allows long term graft survival without immunosuppressants. Lung
transplantation tolerance has not been consistently achieved in either small or large animal models.
Methods: The mechanisms and effectiveness of a tolerance induction protocol consisting of donor specific
transfusion (DST; day 0) and a short course of co-stimulatory blockade (anti-CD154 antibody; days 27,
24, 0 and +4) were studied in the mouse heterotopic tracheal transplant model of chronic lung rejection.
C57BL/6 mice received BALB/c tracheal grafts (day 0) and were treated with DST alone, anti-CD154
alone, the combination (DST/anti-CD154), or no treatment. No non-specific immunosuppressants were
used.
Results: DST/anti-CD154 in combination, but neither treatment alone, markedly prolonged the lumen
patency and survival (.100 days) of fully histo-incompatible allografts (p,0.05 versus control allografts
at every time point studied up to 16 weeks) without immunosuppression. This protocol was donor antigen
specific as third party grafts (C3H ) were promptly rejected. In addition, DST/anti-CD154 did not result in
mixed chimerism but induced transplantation tolerance via a peripheral mechanism(s), which included
significantly reduced cytotoxic T cell activity (p,0.001) and a significantly increased percentage of
CD4+CD25+ cells (p = 0.03).
Conclusions: The DST/anti-CD154 protocol successfully induced and maintained long term, donor specific
tolerance in the mouse heterotopic airway graft model of chronic lung rejection. This finding may lead us
closer to successful tolerance induction in lung transplantation.
L
ung transplantation has become an established therapeu-
tic option for patients with end stage pulmonary disease.
Its success is markedly limited by chronic lung rejection
or obliterative bronchiolitis (OB), manifested clinically as
progressive airway obstruction. Obliterative bronchiolitis is
the leading cause of late death after lung transplantation and
is the principal reason that the 5 and 10 year survival rates
(approximately 45% and 20%, respectively) are 20–30%
lower, on an absolute basis, than those after heart, kidney,
or liver transplantation. Currently available immunosuppres-
sants, which must be maintained for life, are neither
transplant antigen specific nor effective in treating or
preventing chronic graft rejection. In addition, they possess
many serious adverse effects. A more attractive method of
inducing graft acceptance is through selectively coaxing the
recipient’s immune response into accepting the transplanted
organ as self, while maintaining normal immune reactivity
against non-graft foreign antigens. This approach, called
tolerance induction, has become the ultimate goal of
transplant immunology. Tolerance research in the arena of
lung transplantation has been very limited and has lagged
behind that in other organs. In fact, tolerance of lung
allografts has not been consistently achieved in either small
or large animal models.1
While allorecognition, through engagement of the R cell
receptor (TCR) with the donor derived MHC peptide complex,
is the mandatory event for allospecific T cells to recognise
donor antigens (or signal 1), it is the presence or absence of
the ‘‘co-stimulation signal’’ (or signal 2) that educates
allospecific T cells to either become fully activated, prolifer-
ate, and develop into effector cells, or to become anergic or
tolerogenic, respectively.2 The two most extensively studied
co-stimulatory pathways are the B7/CD28 and CD40/CD154
(CD40L).3 Through competitive binding to B7 molecules on
antigen presenting cells (APCs), CTLA-4 Ig (a soluble form of
the high affinity receptor to B7 molecules) blocks CD28
signalling to the T cells, therefore limiting the activation of
the alloreactive T cells. Treatment with CTLA4-Ig alone
supports long term allograft survival of islet cells4 and hearts
in animal models.5 However, since a CD28 independent
CTLA4 signal might deliver a strong negative signal to CD4+ T
cells and thus interrupt the CTLA4/B7 interaction, alloreac-
tive T cells are not effectively shut down.6 Other means by
which to disrupt T cell activation includes blockade of the
CD40/CD154 co-stimulatory pathway which, in turn, limits
the maturation of APCs and down-modulates the B7/CD28
interaction.7 In the mouse model of chronic lung rejection,
the greater importance of CD40/CD154 compared with B7/
CD28 has been demonstrated by the finding that recipient
mice deficient in CD154 (but not CD28) expression on T cells
reject tracheal allografts more slowly than wild-type recipient
mice.8
Translating tolerance protocols from one organ to another
has been elusive. Thus, the success of a tolerance induction
protocol in one organ may not necessarily ensure the success
in others.1 We hypothesise that selective blockade of immune
responses that allows allorecognition of donor antigen by
allospecific T lymphocytes through specific TCRs (signal 1),
but prevents co-stimulatory signalling (signal 2), may
prevent the initiation of rejection in an antigen specific
manner. One tolerance induction protocol—namely,
Abbreviations: APCs, antigen presenting cells; CFSE, carboxy-
fluorescein diacetate succinimidyl ester; CTL, cytotoxic lymphocyte; DST,
donor specific transfusion; MHC, major histocompatibility complex; OB,
obliterative bronchiolitis; TCR, T cell receptor; TR, regulatory T cells
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combined donor specific transfusion (DST) and anti-CD154
monoclonal antibody (DST/anti-CD154)—has emerged as a
robust tolerance induction protocol in non-lung transplant
models including islet,9 heart,10 and skin11 allografts. Its
effectiveness in lung transplantation has not been tested.
Using the mouse model of chronic lung rejection (or
obliterative bronchiolitis) which most faithfully models
chronic airway rejection,12 13 we tested the hypothesis that
DST/anti-CD154 therapy induces lung transplantation toler-
ance and explored the immunological mechanisms of action.
METHODS
Mice
Female BALB/c (H-2d) or third-party C3H (H-2k) donors and
C57BL/6 (H-2b) recipient mice (8–12 weeks old) were used
(Harlan Labs; Indianapolis, IN, USA). Mice were maintained
following the guidelines of the National Institutes of Health
Guide for the Care and Use of Laboratory Animals under an
approved IACUC protocol at the University of North Carolina-
Chapel Hill.
Transplantation
Heterotopic tracheal transplantation surgery, tissue proces-
sing and staining, image acquisition, and the measurement of
lumen fibroproliferation, the determinant of airway rejection,
were performed as previously described.14–17
Treatment protocols
DST consisted of a single dose of 107 freshly isolated donor
splenocytes given to recipients on day 27 relative to
transplantation.18 Briefly, single cell suspensions were
obtained by passing splenocytes through a 70 mm nylon filter
(BD Biosciences, San Jose, CA, USA), subjected to hypotonic
erythrocyte lysis, counted, diluted in 200 ml phosphate
buffered saline (PBS), and transfused into the tail vein of
recipient mice. The hamster anti-mouse CD154 monoclonal
antibody (MR-1, Bioexpress, West Lebanon, NH, USA) was
administered intraperitoneally at a dose of 0.5 mg/mouse
on days 27, 24, 0, and +4. Recipient mice received either of
the treatments, or both combined, or none (fig 1). No
immunosuppressants were used. Tolerance was defined as
survival for .100 days as previously described.18 19
Cytotoxic lymphocyte (CTL) assay
As previously described,20 splenocytes from transplanted or
naı̈ve C57BL/6 mice were restimulated with gamma irra-
diated (20 Gy) donor (BALB/c) or control syngeneic (C57BL/
6) stimulator splenocytes at a 1:1 ratio for 6 days before
testing their efficacy as effector cells. At 37 C̊ in 5% CO2,
effector cells were then co-cultured in triplicates for 4 hours
with 5000 concanavalin-A stimulated [3H]-thymidine
labelled target (allogeneic or self) blast cells with effector to
target cell ratios ranging from 100:1 to 12.5:1 in 96 well
plates. The cells were harvested and the specific [3H] release
was determined using liquid scintillation counting on a
Microtiter Plate Reader (Packard Instrument, Meriden, CT,
USA). Percentage cytotoxicity was calculated as the differ-
ence in spontaneous lysis and targeted release over sponta-
neous lysis.
Carboxy-fluorescein diacetate succinimidyl ester
(CFSE) staining
As previously described,20 single cell suspensions of freshly
isolated splenocytes (107/ml in PBS) were incubated with an
equal volume of 10 mM CFSE (Molecular Probes, Eugene, OR,
USA) in the dark with periodic agitation (37 C̊, 10 min).
Unbound CFSE was quenched with an equal volume of fetal
bovine serum (Sigma-Aldrich, St Louis, MO, USA). In order
to determine the fate of transfused donor splenocytes in vivo,
CFSE labelled cells were washed three times and transfused
into the tail vein of recipient mice. After 12 hours the
fluorescence intensities of single cell suspensions obtained
from the recipient’s spleen, axillary lymph nodes, and the
thymi were analysed by flow cytometry using a FACScan
(Becton Dickinson, San Jose, CA, USA) and analysed with
FlowJo software (Tree Star, San Carlos, CA, USA).
Immunohistochemistry
Whole spleen, lymph node, and thymus were embedded in
Tissue-Tek OTC (Sakura Finetek, Torrance, CA, USA) and
stored at 220 C̊ until use. Frozen sections were air dried,
fixed in chilled acetone, and blocked with 5% normal goat
serum (Jackson ImmunoResearch, West Grove, PA, USA).
The sections were incubated with HRP conjugated rabbit
monoclonal anti-FITC antibody (DakoCytomation,
Carpinteria, CA, USA). Optimal dilutions and incubation
periods were determined empirically. Duplicate sections on
the same slide were incubated with rabbit IgG (Jackson
ImmunoResearch) as a negative isotype control.
Diaminobenzidine (DAB) (Sigma-Aldrich) was used as the
substrate and the sections were counterstained with Light
Green (Fisher Scientific Company, Pittsburgh, PA, USA).
Immunofluorocytochemistry for regulatory T cells
Whole spleen and lymph nodes were incubated with RPMI
medium containing 10% FCS and collagenase IV (1 mg/ml;
Sigma-Aldrich, St Louis, MO, USA) at 37 C̊ for 15 minutes.
Single cell suspensions were obtained by passing splenocytes
through a 70 mm nylon filter (BD Biosciences), subjected to
hypotonic erythrocyte lysis, and collected into cold Dulbecco’s
PBS plus 2% dialysed serum albumin (Sigma-Aldrich). After
blocking with purified rat anti-mouse CD16/32 (III/II FcR,
2.4G2, IgG2b) and 10% v/v mouse IgG (15 min; 4 C̊), cells
(56106) were incubated on ice with FITC conjugated rat anti-
CD4 (RM4-5, IgG2a) and PE conjugated rat anti-CD25 (PC61,
IgG1) or PE conjugated rat anti-CD45RB (anti-B220, clone
RA3-6B2, IgG2a), or appropriate isotype matched Ig controls




























Figure 1 DST/anti-CD154 induces and maintains long term airway
allograft tolerance. Without the use of immunosuppressants, treatment
with DST/aCD154, but not either DST or anti-CD154 alone, maintained
lumen patency and prolonged tracheal allograft survival indefinitely
(.100 days). The freedom from airway rejection in allografts
transplanted into recipients under treatments of DST, anti-CD154, DST/
anti-CD154, or no treatment is shown as the mean percentage of airway
lumen patency (n = 5–11 and SDs (18% for each treatment arm at each
time point). *p,0.05 compared with control allografts at the same time
point.
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USA). Data were acquired on a FACScan and analysed with
FlowJo software.
Statistics
Analyses were performed using the Student’s t test with data
presented as mean (SD) or, if the data were not normally
distributed, non-parametric tests with the data presented as
medians with 25–75% confidence intervals (SigmaStat
Software, SPSS Inc, Chicago, IL, USA) as previously
described.14–17 To test the efficacy of the DST/antiCD154
protocol, different end points in different experimental arms
were compared with t tests at each time point and also by
analysis of variance (ANOVA) which reflected a comparison
across all time points.
RESULTS
Effect of DST/anti-CD154 on transplantation
tolerance of tracheal allografts
Without treatment, tracheal allografts (n = 6–9 at each time
point) were rapidly rejected resulting in nearly complete
airway obliteration at 4 and 5 weeks and complete airway
obliteration within 6 weeks (figs 1 and 2A–C). Treatment
with DST alone resulted in allograft rejection similar to
control allografts (n = 5–8 at each time point; p.0.2 at 3, 4,
5, and 6 weeks; figs 1 and 2D–F). Treatment with anti-
CD154 alone modestly prolonged allograft survival up to
5 weeks (n = 7–8 at each time point; p(0.03 at 3, 4, and
5 weeks). However, the grafts underwent nearly com-
plete lumen obliteration at 6 weeks (n = 6; p = 0.38) and
complete lumen obliteration at 8 weeks (n = 7; p = 0.40),
similar to control allografts (figs 1 and 2G–I). In sharp
contrast, combined treatment with DST/anti-CD154 resulted
in markedly preserved allograft lumen patency and
prolonged survival (.100 days) (n = 6–11, p,0.05 v control
allografts at each time point from 3 to 16 weeks and
p,0.001 using an ANOVA; figs 1 and 2J–N). In addition,
with DST/anti-CD154 treatment, tracheal grafts main-
tained normal epithelialisation for up to 8–10 weeks
and cuboidal epithelialisation for up to 14 weeks (fig 2O–
S), but interestingly had varying amounts of lymphocytic
infiltrates.
Effect of DST/anti-D154 on donor specific T
lymphocyte cytotoxicity
The capability of allograft recipients to generate donor
specific immune responses was tested by examining CTL
activity. Two weeks after transplantation, T lymphocytes
from recipient mice treated with the DST/anti-CD154
combination showed a significant (p,0.001) decrease in
cytotoxicity against donor specific (BALB/c) target cells when
compared with those from recipients who received DST
alone, anti-CD154 alone, or no treatment (fig 3A). Similar
results were observed at 4 weeks after transplantation (data
not shown).
Effect of DST/anti-CD154 on donor specific
transplantation tolerance
Third party allografts or third party DST were used to
examine the donor specificity of the DST/anti-CD154
protocol. While treatment with BALB/c DST/anti-CD154 in
the C57BL/6 recipients markedly prolonged BALB/c
tracheal allograft survival, third party C3H allografts, under
BALB/c DST/anti-CD154 treatment, were rejected similar to
Figure 2 Representative histology of tracheal allografts treated with DST/anti-CD154. Tracheal allografts transplanted into recipients who received
DST/anti-CD154 (J–N) displayed a complete or nearly complete patent airway lumen for up to 16 weeks (stain: H&E, magnification 106). This was not
the case for those allografts transplanted into recipients who received DST alone (D–F), anti-CD154 alone (G–I), or no treatment (A–C). Of note, under
DST/anti-CD154 treatment, tracheal allografts maintained epithelialisation for up to 16 weeks and displayed a gradual progressive loss of
differentiated epithelium over time (O–S, magnification 406). Ep, epithelium.
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C3H allografts under anti-CD154 treatment alone at
6 weeks (n = 6, median patency 15 (25–75% CI 6–22) v 0
(0.22–0.85); p.0.2), with complete lumen obliteration
at 8 weeks (n = 4, median patency 0.0 (0–0) v 0.0 (0–0),
p.0.2). In addition, BALB/c allografts transplanted into
the C57BL/6 recipients under C3H DST/anti-CD154 treat-
ment were rejected, similar to BALB/c allografts under
anti-CD154 treatment alone (n = 4, p.0.2 both at 6 and
8 weeks). Finally, C3H allografts (n = 5) transplanted at
week 4 into C57BL/6 mice that had already received a
BALB/c allograft at day 0 under cover of BALB/c DST/
anti-CD154 were fully rejected (0.0 (0.0)% lumen patency)
at 5 weeks, not significantly different (p.0.2) from
C3H allografts (n = 5) placed in C57BL6 animals
without treatment, but significantly different (p = 0.01,
Wilcoxon rank sum test) from similarly treated C57BL6
animals that received a second BALB/c graft (100 (0.0)% at
5 weeks).
Kinetics of transfused donor splenocytes in recipient’s
secondary lymphoid organs
In order to determine the fate and kinetics of transfused
donor cells in vivo, donor (BALB/c) splenocytes were labelled
with immunofluorescence dye before intravenous injection
into naı̈ve recipient (C57BL/6) mice (fig 4A–C). The
frequencies of the transfused CFSE positive donor cells
within the recipient’s primary (thymus) and secondary
(spleen and transplant draining (axillary) lymph nodes)
lymphoid organs at 12, 24, 48 and 72 hours after transfusion
are shown in fig 4D. At 24 hours after the transfusion, donor
splenocytes were detected within the white pulp areas of the
spleen (,0.35% of the resident splenocytes; figs 4D and 5A–
C) and, to a lesser extent, within the non-follicular areas of
the axillary lymph nodes (,0.15% of the resident lympho-
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Figure 3 Recipients treated with DST/anti-CD154 exhibited reduced
donor specific cytotoxic lymphocytes (CTLs). The secondary CTL assays
were performed at 2 weeks after transplantation on splenocytes
derived from recipient mice who received different treatments (n = 3
for each group). Isolated splenocytes were re-stimulated with irradiated
spleen cells from mice of the same strain as donor grafts. After
6 days in culture, the re-stimulated recipient cells were harvested and
assayed for the ability to lyse radioactive labelled target cells.
Under different treatments, CTLs from recipients of H2d grafts variably
lysed allogeneic H2d targets (A), but did not lyse syngeneic H2b
control targets (B). The x axis shows effector to target cell ratios. Data are
shown as mean (SD) percentage lysis in triplicate cultures from three
animals and are representative of two separate experiments.
The SD bars on the no treatment group are too small to be seen on the
graph.
Figure 4 Flow cytometry shows that donor splenocytes home to
secondary and primary lymphoid organs. Transfused donor cells were
traced in vivo using CFSE labelling. Freshly isolated splenocytes readily
acquired intracellular CFSE label (A, light microcopy; B fluorescence
microscopy; C, flow cytometry). As an internal control, unlabelled
splenocytes were mixed with labelled splenocytes (C). (D) A small
number of transfused cells migrated to, and then rapidly disappeared
from, the recipient lymphoid organs. Naı̈ve C57BL/6 mice were
transfused with 107 freshly isolated CFSE labelled BALB/c splenocytes.
The frequencies of CFSE positive cells within lymphoid organs (spleen,
transplant draining lymph nodes, and thymus) were determined 12, 24,
48 and 72 hours after transfusion (n = 4 at each time point). The y axis
shows the percentages of cells within the recipient primary (thymus) and
secondary (spleen and transplant draining lymph nodes) lymphoid
organs. The fluorescence intensities of single cell suspensions from
primary and secondary lymphoid organs were acquired by FACScan
and analysed with FlowJo with a minimum of 106 events for each
analysis. Data are shown as mean (SD) percentages of CFSE positive
cells within the whole respective lymphoid organs and are representative
of three separate experiments.
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within these lymphoid organs at 72 hours after transfusion
(fig 4D). No significant donor cells were detected within
the thymus at any time point (,0.001%, fig 4D). When
anti-CD154 was co-administered, the kinetics of transfused
donor splenocytes was not altered (data not shown).
Effect of DST/anti-CD154 protocol on frequencies of
CD4+CD25+ or CD4+CD45RBlo regulatory/suppressor
T cells
Using flow cytometry, CD4+ T cells derived from the
recipient’s secondary lymphoid organs at 2 and 4 weeks
after transplantation were gated according to the surface
expression of CD25 or CD45RB (fig 6A and B). The
percentage of splenic CD4+CD25+ cells was significantly
higher in the DST/anti-CD154 group than in the untreated
transplant control group (p = 0.03), but only trended toward
being higher compared with the group treated with anti-
CD154 alone (p = 0.19; 2 week data shown in fig 6C). Similar
results were found in both the CD4+CD25+ cells derived from
recipient’s draining lymph nodes and splenic CD4+CD45RBlo
cells at both 2 and 4 weeks (data not shown).
DISCUSSION
We report the long term survival of fully histo-incompatible
airway allografts without the use of immunosuppressants in
the mouse model of chronic lung rejection. This is one of the
first reports where tolerance has been reliably achieved in any
lung rejection model and, in addition, in an animal model of
chronic graft rejection. Donor specific transplantation toler-
ance was successfully induced and maintained by a single
treatment of donor splenocytes in combination with a short
course of antagonistic non-T cell depleting anti-CD154
monoclonal antibody (DST/anti-CD154). By providing donor
antigen specific signal while blocking the co-stimulation to
the recipient’s T cells within the secondary lymphoid organs,
this combination protocol markedly suppressed the alloreac-
tive T cell effector response and achieved donor specific
transplantation tolerance. This protocol clearly induced
transplantation tolerance via a peripheral mechanism(s) as
it did not result in mixed chimerism or central deletion. In
addition, we found that, during the induction phase of
transplantation tolerance, the percentages of CD4+CD25+ or
CD4+CD45RBlo regulatory/suppressor T cells within the
spleen and draining lymph nodes of the recipient with the
DST/anti-CD154 treatment were significantly increased com-
pared with the no treatment group.
Alloimmunity is initiated by the recognition of alloantigen
(allorecognition) present on the surface of donor (direct
Figure 5 Representative histology primary and secondary lymphoid organs of recipient 12 hours after donor specific transfusion. Sections of spleen
were examined by immunohistochemistry staining for CFSE label. The section was incubated with HRP conjugated rabbit anti-FITC antibody and the
colour was developed with DAB. Transfused donor CFSE labelled T cells (dark brown) were localised primarily in the white pulp of the spleen (A–C) or



































































Figure 6 DST/anti-CD154 increased the percentage of CD4+CD25+
regulatory T cells. Splenocytes were obtained from recipient mice
2 weeks after transplantation. Representative flow cytometric histograms
of CD4+CD25) and CD4+CD45RBlo cells are shown in (A) and (B),
respectively. CD4+ T cells were evaluated according to the presence of
surface expression of CD25 or CD45RB marker (in boxes). A minimum
of 105 events was acquired for each analysis. (C) Mean percentage of
CD4+CD25+ cells was significantly increased in the DST/anti-CD154
treatment group compared with the untreated transplant group ((5.2
(1.3)% v 4.4 (0.8)%, p = 0.03). The results are representative of two
separate experiments performed at 2 and 4 weeks after transplantation.
Lymph node analyses gave similar results (data not shown).
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pathway) and/or recipient (indirect pathway) APCs to
recipient T cells (signal 1).2 With the help of co-stimulatory
signals (signal 2), allospecific T cells then become activated,
proliferate, and differentiate into effector cells that, through
powerful, complex, and well orchestrated immune cascades,
ultimately destroy the graft. In this study, using the mouse
heterotopic tracheal transplant model for chronic lung
rejection, we evaluated the effectiveness of a combination
DST/anti-CD154 protocol by exposing the recipient to donor
antigens (signal 1) concomitant with co-stimulation (signal
2) blockade before transplantation. We found that the DST/
anti-CD154 protocol was very effective in inducing and
maintaining airway allograft tolerance, in keeping with
studies in other transplant mouse models showing improved
islet, heart and skin allograft survival in euthymic and
thymectomised recipients.9–11 In lung transplantation, several
studies have reported the prolongation of murine heterotopic
tracheal allograft survival without the use of immunosup-
pressants.21–25 However, those studies found significant
improvement of end points of allograft survival at no more
than 42 days after the last treatment. In addition, when
lymphocyte proliferation (MLR) was reported, the treatment
did not result in donor specific suppression.22 23 In sharp
contrast, we have shown that the DST/anti-CD154 protocol
maintained nearly complete airway patency beyond 100 days
after the final anti-CD154 administration, indicating that the
DST/anti-CD154 protocol is by far the most effective protocol
to date for inducing tolerance in murine models of chronic
lung rejection. We also showed that this state of transplanta-
tion tolerance was donor specific since the (BALB/c) DST/
anti-CD154 did not prolong survival of the fully histo-
incompatible third party (C3H) grafts nor did the third party
(C3H) DST/anti-CD154 prolong survival of BALB/c allografts
in the C57BL/6 recipients, and nor could third party (C3H)
grafts be successfully engrafted into C57BL/6 mice who had
received a BALB/c graft under cover of (BALB/c) DST/
antiCD154. Donor specific signal provided by the DST/anti-
CD154 protocol may selectively capture allospecific T cell
repertoires and be responsible for this distinction.
The mechanism(s) by which the DST/anti-CD154 protocol
induces tolerance has not been fully elucidated but has been
studied in non-lung transplantation models. DST/anti-CD154
induces Th2 polarisation10 and the deletion of the alloreactive
CD8+ cells.26 These effects appear to be CTLA4 dependent11
and require the presence of a subset of CD4+ T cells,
presumably regulatory/suppressor cells.11 27 In this study we
have shown, firstly, that each component was mandatory
since treatment with DST alone or anti-CD154 alone was far
less effective than the combination. This finding is consistent
with previous findings showing that donor whole blood
transfusion modestly prolonged the longevity of human renal
allografts28 and that anti-CD154 used as monotherapy did not
induce mouse cardiac allograft tolerance29 due to its inability
to block rejection elicited by CD8+ or CD4+ effector T cells.
Secondly, while it remains controversial,30 it is generally
believed that antigen recognition occurs in the secondary
lymphoid organs.31 32 In this study we showed that DST cells
homed to the recipient’s secondary lymphoid organs,
primarily to the white pulp of the spleen or non-follicular
areas of the lymph nodes, respectively, extending a previous
observation in the spleen after allogeneic B cell transfusion.33
In addition, the rapid disappearance of transfused donor cells
from these lymphoid organs (within 72 hours) in the
presence or absence of anti-CD154 suggests that mixed
chimerism was not achieved, corroborating and extending
the findings of others.18 26 Thirdly, transfused donor cells
were undetectable in the recipient’s thymi at any time during
the study, suggesting that central (intrathymic) deletion is
less likely to account for tolerance induction by this protocol.
Finally, varying numbers of lymphocytes infiltrated the
tolerised allografts but did not lead to tissue rejection,
suggesting either non-specific inflammation (that is, T cells
without donor specificities) or the recruitment of anergic T
cells. Taken together, our data are in agreement with the
hypothesis that the DST/anti-CD154 protocol induces trans-
plantation tolerance by a peripheral mechanism(s) leading to
a suppressed donor specific CTL response at an effector
function level and, although not studied here, the possibility
of generating anergic T cells that traffic to the graft.
Regulatory T (TR) cells, including naturally arising TR cells
(CD4+CD25+ or CD4+CD45RBlo) have been evident with
many tolerance inducing protocols in many transplant and
autoimmunity models and may be responsible for tolerance
induction. While others have suggested that, under the DST/
anti-CD154 protocol, the presence of a subset of CD4+ cells is
critical for prolonged allograft survival,11 18 27 34 they have not
identified this subset of CD4+ cells. In this study we found a
significant increase in the percentage of CD4+CD25+ and
CD4+CD45RBlo TR cells within the spleen and lymph nodes of
recipient animals treated with this protocol at 2 and 3 weeks
after transplantation, suggesting a role for these cells in
tolerance induction. However, since the functions of these
cells were not evaluated in vitro or in vivo and we did not
measure FoxP3 expression, we cannot prove that these cells
were responsible for tolerance induction. The precise
mechanisms by which the DST/anti-CD154 protocol induces
and maintains lung transplant tolerance, including the
involvement of TR cells, have yet to be elucidated and are
under current investigation in our laboratory.
This study has several potential limitations. Firstly, the
mouse model of chronic lung rejection has limitations as
previously described,14–17 but it remains one of the best (if not
the best) model for chronic rejection since orthotopic models
do not characteristically reproduce human OB.35 36
Nonetheless, this is the first study to demonstrate the use
of this model of chronic lung rejection and tolerance
induction protocol to accomplish interventional lung trans-
plantation tolerance. The merits of this model therefore argue
for further testing of lung transplant tolerance inducing
protocols using this and other models, including those that
primarily model acute rejection (such as the rat orthotopic
model). Secondly, the brevity and simplicity of the DST/anti-
CD154 protocol obviates the need for non-specific immuno-
suppression. However, in an effort to facilitate pre-emptive
tolerance induction of the allospecific T cell compartment,
DST/anti-CD154 must be introduced before transplantation.
Application of this protocol would therefore be restricted
from the cadaveric donor transplant setting in clinical
medicine. Evaluation of the effectiveness of this type of
protocol—when DST is given at the time of or a few hours
before transplantation (that is, at 21 to 26 hours)—are
being investigated currently with the goal of improving its
clinical application. Thirdly, although the operational criteria
defining indefinite graft tolerance is graft survival for more
than 100 days, tracheal allografts under the DST/anti-CD154
protocol may not truly maintain indefinite tracheal graft
survival as they displayed a gradual progressive loss of
differentiated epithelium over time and completely
lost epithelialisation between 14 and 16 weeks. The loss of
the epithelial lining of the murine tracheal allograft
lumen has been consistently observed preceding lumen
obliteration,12–15 37 38 suggesting that these grafts may be
rejected eventually. The potential benefits of additional DST
and/or anti-CD154 treatment(s) used at later time points
after transplantation to suppress new allospecific thymic
emigrants remain to be determined.
In conclusion, long term donor specific airway allograft
tolerance in the stringent, fully histo-incompatible, heterotopic
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tracheal transplant model of chronic lung rejection can be
induced and maintained by the combination treatment of a
single donor specific transfusion and a short course of the
monoclonal anti-CD154 antibody around the time of trans-
plantation. This finding has brought us a significant step closer
to successful tolerance induction in lung transplantation.
Further studies are needed to identify the mechanisms by
which this protocol achieves tolerance and to modify this
protocol to become more clinically applicable, thereby position-
ing clinical lung transplant tolerance trials into situations
currently occupied only by other organ transplants.
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